


sight

Blood Diagnostics Reimagined

OLO



← TW-0002-7491-02 +22

09:55 OLO



45%




Lab-grade Results

Accurate

Breakthrough technology combining digital microscopy and artificial intelligence to deliver no-compromise CBC results.

FDA 510(k)* clearance based on substantially equivalent clinical evidence compared to state-of-the-art hematology analyzers.



Comparison studies performed at 3 US sites to evaluate OLO vs a lab reference device.

*For full indications for use and safety information, please refer to the Quality and Compliance page at www.sightdx.com.

Comprehensive

CBC with 5-part differential (19 parameters)

CBC Parameters			
WBC	White Blood Cell Count	RDW	Red Blood Cell Distribution Width
RBC	Red Blood Cell Count	PLT	Platelet Count
HGB	Hemoglobin	NEUT%/#	Neutrophil Percent and Count
HCT	Hematocrit	LYMPH%/#	Lymphocyte Percent and Count
MCV	Mean Corpuscular Volume	MONO%/#	Monocyte Percent and Count
MCH	Mean Corpuscular Hemoglobin	EOS%/#	Eosinophil Percent and Count
MCHC	Mean Corpuscular Hemoglobin Concentration	BASO%/#	Basophil Percent and Count

Abnormal morphology detection

WBC Flags		IP Messages	
Abnormal Distribution	Abnormal Morphology	Suspected PLT Clumps	Suspected WBC agglutination
Neutrophils	Blasts	Suspected giant PLT	Suspected Dual RBC population
Lymphocytes	Immature Granulocytes	Suspected RBC agglutination	Abnormal PLT distribution
Monocytes	Variant Lymphocytes	Suspected high reticulocyte	
Eosinophils	Nucleated RBCs	Suspected low reticulocytes	
Basophils		Abnormal WBC classification	

Extensive reportable and display range

	Reportable Range	Display Range		Reportable Range	Display Range
WBC	0.18 - 100.13 10 ³ /μL	0.00 - 999.99 10 ³ /μL	NEUT%	0.0 - 100%	0.0 - 100.0 %
RBC	1.22 - 7.55 10 ⁶ /μL	0.00 - 999.99 10 ⁶ /μL	NEUT#	0.00 - 100.13 10 ³ /μL	0.00 - 999.99 10 ³ /μL
PLT	18 - 1028.5 10 ³ /μL	0 - 99999 10 ³ /μL	LYMPH%	0.0 - 100%	0.0 - 100.0 %
HGB	4.0 - 21.75 g/dL (40-215g/L)	4.0 - 25.0 g/dL (40-250 g/L)	LYMPH#	0.00 - 100.13 10 ³ /μL	0.00 - 999.99 10 ³ /μL
HCT	15.2 - 63.7 %	0.0 - 100.0 %	MONO%	0.0 - 100%	0.0 - 100.0 %
MCV	57.3 - 121.2 fL	0.0 - 999.9 fL	MONO#	0.00 - 100.13 10 ³ /μL	0.00 - 999.99 10 ³ /μL
RDW	10.6 - 29.4 %	0.0 - 100.0 %	EOS%	0.0 - 100%	0.0 - 100.0 %
MCH	14.9 - 42.0 pg	0.0 - 9999.9 pg	EOS#	0.00 - 100.13 10 ³ /μL	0.00 - 999.99 10 ³ /μL
MCHC	NA	0.0 - 9999.9 g/dL (0-99999 g/L)	BASO%	0.0 - 100%	0.0 - 100.0 %
			BASO#	0.00 - 100.13 10 ³ /μL	0.00 - 999.99 10 ³ /μL

Complete Blood Count in Minutes



Test Anyone, Anywhere*

Wide Indication for Use

- Any clinical condition
- Ages 3 months+

Rapid Testing and Results

- Only 2 drops of blood (27 μ l) from a finger prick or a venous sample
- Results ready in minutes on touchscreen interface, printout, email or via LIS
- Connectivity to LIS, Middleware and EPR

Simple to Install and Operate

- Factory calibrated and remote servicing
- Short training required with touchscreen instructions for each use
- Automatic internal quality control and failsafe system to ensure integrity of results

Easy and Cost Effective to Maintain

- No reagent management
- Minimize quality control procedures and expenses
- No routine maintenance and calibration for users




*In the US, OLO is FDA (510k) cleared for use in CLIA-certified moderate complexity settings



Design Features

- **Dimensions** | 12.7 inch x 11.2 inch x 10 inch
- **Weight** | 22 lbs
- **Operating at Room Temperature** | 18-30°C
- **Test Kit Shelf Life** | 13 months
- **Test Kit Storage Condition** | stored at 18-26°C



Improved Efficiency

For Distribution In The United States

sight



About Sight Diagnostics

Founded in 2011, Sight Diagnostics® is a blood diagnostic company that combines machine vision and AI to improve health through fast, convenient and accurate diagnostic testing. Sight's technology, developed over almost a decade of research, represents innovations in blood sample preparation and optics, as well as advancements in chemistry, biology, physics and computer science.

Sight's first product, Parasight™, has been used to detect malaria in almost 1 million tests across 24 countries. OLO, Sight's latest blood analyzer aimed at improving how Complete Blood Count (CBC) tests are performed, received FDA 510(k) clearance for use in moderately complex laboratory settings. With just 2 drops of blood obtained from a finger prick or venous sample, OLO digitizes each blood sample with more than 1,000 high resolution images to provide accurate, lab-grade CBC results in minutes.

Across Europe and the US, OLO has been adopted by both public and private healthcare institutions. Sight has also established partnerships to bring OLO to market in Asia, South America, Africa and Australia. Sight is committed to applying its AI-based technology to transform health systems in a world where decentralized diagnostics play an increasingly important role in patient outcome.

www.sightdx.com

USA
sales-us@sightdx.com

UK
sales-uk@sightdx.com

Israel
sales-il@sightdx.com